<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Muir-Torre syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Muir-Torre syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Muir-Torre syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia Tai, MB, BS, DMRT, FRCR, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Schwartz, MD, MPH, DSc (Hon), MAE, FRCP Edin</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">June K Robinson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H253201701"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Muir-Torre syndrome (MIM #158320) is a rare, hereditary condition characterized by the association of at least one, but often multiple, sebaceous cutaneous neoplasms and at least one, but sometimes multiple, often low-grade, synchronous or metachronous, visceral malignancies [<a href="#rid1">1,2</a>]. Muir-Torre syndrome is caused by germline variants in the deoxyribonucleic acid (DNA) mismatch repair (MMR) genes and is considered a phenotypic variant of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma syndrome [HNPCC]). However, approximately one-third of cases of Muir-Torre syndrome are caused by <em>MUTYH</em> variants and may represent a clinical phenotype of <em>MUTYH</em>-associated polyposis, an autosomal recessive polyposis syndrome caused by biallelic pathogenic variants in the base excision repair gene <em>MUTYH</em>.</p><p>This topic will discuss the pathogenesis, clinical features, diagnosis, and management of Muir-Torre syndrome. Lynch syndrome and <em>MUTYH-</em>associated polyposis are discussed separately. Sebaceous carcinoma is also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86140.html" rel="external">"<i>MUTYH</i>-associated polyposis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/97893.html" rel="external">"Sebaceous carcinoma"</a>.)</p><p></p><p class="headingAnchor" id="H2860297934"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Muir-Torre syndrome is a variant of Lynch syndrome, which accounts for approximately 3 percent of newly diagnosed cases of colorectal and endometrial cancers. Among individuals with Lynch syndrome, approximately 9 percent have Muir-Torre syndrome [<a href="#rid3">3,4</a>]. It is estimated that in the general population, 1 in 279 individuals carry variants in any DNA mismatch repair (MMR) genes associated with Lynch syndrome [<a href="#rid5">5</a>]. Approximately one-third of Muir-Torre syndrome cases represent a clinical phenotype of <em>MUTYH</em>-associated polyposis. (See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/86140.html" rel="external">"<i>MUTYH</i>-associated polyposis"</a>.)</p><p>Muir-Torre syndrome is more frequent in males (male-to-female ratio 3:2), with a median age of onset of cutaneous malignancies of 53 years (range 23 to 89 years) [<a href="#rid6">6</a>]. Muir-Torre syndrome has been rarely reported in solid organ transplant recipients who developed sebaceous carcinomas and other visceral malignancies [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H253201803"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H524599165"><span class="h2">Mismatch repair gene variants</span><span class="headingEndMark"> — </span>In approximately two-thirds of cases, Muir-Torre syndrome is caused by dominant germline inactivating variants of DNA mismatch repair (MMR) genes. The human DNA MMR system includes the <em>Escherichia coli</em> homolog genes <em>MSH2</em>, <em>MSH3</em>, <em>MSH6</em>, and <em>MLH1</em> and the yeast homologue gene <em>PMS2</em>. The products of these genes are responsible for maintaining the genomic integrity by correcting base substitution mismatches and small insertion-deletion mismatches generated by errors in base pairing during DNA replication.</p><p>In contrast with Lynch syndrome, in which germline variants are almost equally distributed across all MMR genes, approximately 90 percent of patients with Muir-Torre syndrome harbor germline variants in <em>MSH2</em>, with less than 10 percent harboring <em>MLH1</em> variants [<a href="#rid9">9</a>]. Rare cases of Muir-Torre syndrome are associated with isolated germline variants in <em>MSH6</em> or <em>PMS2</em> [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H66395558"><span class="h2">Microsatellite instability</span><span class="headingEndMark"> — </span>Microsatellite instability (MSI) is the hallmark of MMR gene deficiency. Microsatellites are short, repetitive DNA sequences, typically mononucleotide or dinucleotide tandem repeats, that are susceptible to mutations during DNA replication. The loss of DNA MMR function in tumor tissue due to germline and/or somatic inactivating mutations of MMR genes leads to the accumulation of mutations across the genome and, mainly, in the microsatellite repetitive sequences, creating a molecular phenotype known as MSI [<a href="#rid10">10</a>]. Mutations in <em>MLH1</em> and <em>MSH2</em> have the most severe effect, producing a high microsatellite instability phenotype (MSI-H). An MSI-H phenotype can be demonstrated in nearly all cutaneous and visceral tumors from patients with Muir-Torre syndrome [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer", section on 'Mismatch repair genes'</a>.)</p><p class="headingAnchor" id="H2563982816"><span class="h2"><i>MUTYH</i> gene</span><span class="headingEndMark"> — </span>Approximately one-third of patients with Muir-Torre syndrome do not display pathogenic variants in <em>MLH1</em>, <em>MSH2</em>,<em> MSH6</em>, or MSI. They comprise a subtype of Muir-Torre syndrome, called Muir-Torre syndrome type 2, which is due to germline biallelic inactivation of the base excision repair gene mutY homolog (<em>MUTYH</em>)<em> </em>on chromosome 1p and inherited in an autosomal recessive manner with low to moderate penetrance [<a href="#rid2">2,13-15</a>]. Coexisting germline <em>MSH2</em> and <em>MUTYH</em> mutations were described in one patient with Muir-Torre syndrome [<a href="#rid16">16</a>]. Sebaceous tumors in Muir-Torre syndrome type 2 do <strong>not</strong> show MSI.</p><p><em>MUTYH</em> variants are associated with an attenuated form of familial adenomatous polyposis, frequently referred to as <em>MUTYH</em>-associated polyposis, characterized by recessive inheritance, older age of onset, and fewer colorectal adenomas. Cases of sebaceous adenomas in patients with <em>MUTYH</em>-associated polyposis have been reported [<a href="#rid14">14,17,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/86140.html" rel="external">"<i>MUTYH</i>-associated polyposis"</a> and  <a class="medical medical_review" href="/z/d/html/2593.html" rel="external">"Clinical manifestations and diagnosis of familial adenomatous polyposis", section on 'Attenuated FAP'</a>.)</p><p class="headingAnchor" id="H617186181"><span class="h2">Immunosuppression</span><span class="headingEndMark"> — </span>Rare cases of confirmed Muir-Torre syndrome have been reported in solid organ transplant recipients who developed single or multiple sebaceous tumors showing loss of MMR proteins on immunohistochemistry (IHC) or MSI analysis, with or without concurrent visceral cancers at the time of sebaceous tumor diagnosis [<a href="#rid7">7,8,19</a>]. Immunosuppression may have unmasked a latent Muir-Torre syndrome in these patients.</p><p>Of note, MSI has been detected in sebaceous tumors occurring in organ transplant recipients in the absence of germline mutations in MMR genes [<a href="#rid20">20</a>]. The loss of MMR proteins in these tumors may be due to de novo somatic mutations in MMR<em> </em>genes or <em>CDKN2A</em> gene promoter hypermethylation induced by immunosuppressive agents, particularly <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid8">8,21</a>].</p><p class="headingAnchor" id="H253201821"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Muir-Torre syndrome is characterized by the association of at least one sebaceous skin tumor and/or keratoacanthoma  (<a class="graphic graphic_picture graphicRef73408" href="/z/d/graphic/73408.html" rel="external">picture 1</a>) and at least one synchronous or metachronous, visceral malignancy.</p><p class="headingAnchor" id="H3808336126"><span class="h2">Sebaceous tumors</span><span class="headingEndMark"> — </span>Sebaceous adenomas and sebaceous carcinomas are the most typical tumors in patients with Muir-Torre syndrome [<a href="#rid1">1</a>]. Sebaceous adenoma is most common and considered the most specific marker of Muir-Torre syndrome [<a href="#rid9">9,22</a>]. Sebaceous adenoma and sebaceous carcinoma present as yellowish or skin-colored papules, usually &lt;0.5 cm in diameter  (<a class="graphic graphic_picture graphicRef98399 graphicRef70403" href="/z/d/graphic/98399.html" rel="external">picture 2A-B</a>). They show a predilection for the head and neck region and, particularly, the periocular area in sporadic cases, whereas in patients with Muir-Torre syndrome, these tumors are predominantly found on the trunk [<a href="#rid23">23</a>]. Because sebaceous tumors precede the development of internal malignancies in over one-half of patients, molecular testing of the skin tumor for mismatch repair (MMR) defects in select patients is critical to early diagnosis [<a href="#rid24">24</a>]. (See <a class="local">'Indications for tumor testing'</a> below.)</p><p>Other tumors that can be seen in patients with Muir-Torre syndrome include:</p><p class="bulletIndent1"><span class="glyph">●</span>Basal cell carcinoma with sebaceous differentiation (sebaceous epithelioma)</p><p class="bulletIndent1"><span class="glyph">●</span>Histologically typical keratoacanthoma</p><p class="bulletIndent1"><span class="glyph">●</span>Keratoacanthoma with sebaceous differentiation</p><p class="bulletIndent1"><span class="glyph">●</span>Cystic sebaceous neoplasms</p><p class="bulletIndent1"><span class="glyph">●</span>True sebaceous cysts</p><p></p><p>These tumors tend to occur at an earlier age than the sporadic counterparts and can precede, occur concurrently, or follow the diagnosis of internal malignancy [<a href="#rid25">25</a>]. They can be solitary or number up to hundreds, ranging in size from a few millimeters to several centimeters [<a href="#rid26">26</a>].</p><p>The presence of Fordyce spots (ectopic sebaceous glands) on the vestibular oral mucosa has been suggested as an additional clinical feature of Muir-Torre syndrome  (<a class="graphic graphic_picture graphicRef69406" href="/z/d/graphic/69406.html" rel="external">picture 3</a>) (see  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Fordyce granules'</a>). In a study including 13 patients with Muir-Torre syndrome and confirmed germline MMR mutations and 140 healthy individuals, Fordyce spots were found in all patients with Muir-Torre syndrome but only in 9 (6.4 percent) of the controls [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H93607439"><span class="h2">Visceral cancers</span><span class="headingEndMark"> — </span>Internal malignancies most frequently associated with Muir-Torre syndrome include colorectal cancer and genitourinary cancer, including endometrial, ovarian, urothelial, and prostate cancer [<a href="#rid2">2,9,28,29</a>]. Breast, pancreatic, hepatobiliary, gastric, lung, brain, and hematologic cancers have also been reported in association with Muir-Torre syndrome [<a href="#rid30">30-35</a>].</p><p>Colorectal cancer is the most common visceral neoplasm associated with Muir-Torre syndrome. Compared with sporadic colorectal cancers, lesions are more often located in the proximal colon than in the distal colon and develop 15 to 20 years earlier, with a median age of onset of 50 years [<a href="#rid1">1</a>].</p><p>Colonic polyps may also be found in patients with the autosomal recessive subtype of Muir-Torre syndrome (Muir-Torre syndrome type 2) due to <em>MUTYH</em> variants [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/86140.html" rel="external">"<i>MUTYH</i>-associated polyposis"</a>.)</p><p class="headingAnchor" id="H3523105746"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2548553158"><span class="h2">Diagnostic approach</span><span class="headingEndMark"> — </span>Muir-Torre syndrome is suspected in patients presenting with one or multiple sebaceous tumors, especially if occurring at an early age and located in extraocular or non-head and neck areas. The diagnostic approach involves the following steps  (<a class="graphic graphic_algorithm graphicRef131495" href="/z/d/graphic/131495.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of the patient's risk of having Muir-Torre syndrome using the clinical criteria included in the Mayo score (age ≤60 years, number of sebaceous tumors, personal and family history of malignancy) (see <a class="local">'Clinical criteria (the Mayo Muir-Torre syndrome risk score)'</a> below) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing of sebaceous tumors for mismatch repair (MMR) deficiency with immunohistochemistry (IHC) (see <a class="local">'Tumor testing'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microsatellite analysis of sebaceous tumors (see <a class="local">'Microsatellite instability analysis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing for germline variants in the <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em>, and <em>PMS2</em> genes (see <a class="local">'Genetic testing'</a> below)</p><p></p><p class="headingAnchor" id="H922222399"><span class="h2">Clinical criteria (the Mayo Muir-Torre syndrome risk score)</span><span class="headingEndMark"> — </span>The Mayo Muir-Torre syndrome score was developed to identify patients with the highest risk of having Muir-Torre syndrome [<a href="#rid36">36</a>]. It is highly accurate in discriminating patients with and without Muir-Torre syndrome (area under the receiving operator characteristics [ROC] curve 0.96 [95% CI 0.93-1.00]) [<a href="#rid36">36</a>].</p><p>The Mayo Muir-Torre syndrome score is based on the following clinical criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;60 years at first presentation of sebaceous tumors, including sebaceous adenomas, sebaceous epitheliomas, and sebaceous carcinomas (score = 1)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two or more sebaceous tumors (score = 2)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Personal history of any Lynch-related cancers (score = 1)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of any Lynch-related cancers (score = 1)</p><p></p><p>Patients with a Mayo Muir-Torre syndrome <strong>score</strong> <strong>≥2</strong> are very likely to have Muir-Torre syndrome and should undergo further evaluation with genetic testing for germline variants of MMR genes  (<a class="graphic graphic_algorithm graphicRef131495" href="/z/d/graphic/131495.html" rel="external">algorithm 1</a>) [<a href="#rid36">36</a>]. (See <a class="local">'Genetic testing'</a> below.)</p><p>It is reasonable that young patients with extraocular or periocular sebaceous tumors who do not meet the Mayo Muir-Torre syndrome criteria have their tumor tested with IHC for loss of expression of MMR proteins [<a href="#rid37">37,38</a>]. (See <a class="local">'Immunohistochemistry'</a> below.)</p><p class="headingAnchor" id="H253202019"><span class="h2">Tumor testing</span><span class="headingEndMark"> — </span>Tumor testing for lack of MMR protein expression with IHC or microsatellite instability (MSI) analysis can be used as an initial screening test for Muir-Torre syndrome, particularly in patients who lack the clinical criteria included in the Mayo score  (<a class="graphic graphic_algorithm graphicRef131495" href="/z/d/graphic/131495.html" rel="external">algorithm 1</a>) [<a href="#rid22">22,39</a>]. (See <a class="local">'Immunohistochemistry'</a> below and <a class="local">'Microsatellite instability analysis'</a> below.)</p><p class="headingAnchor" id="H2699260888"><span class="h3">Indications for tumor testing</span><span class="headingEndMark"> — </span>Because cutaneous sebaceous neoplasms are rare in the general population and are associated with Muir-Torre syndrome in a high proportion of cases, some experts advocated universal testing for all sebaceous neoplasms, based on the relatively high rates of MMR IHC positivity detected in unselected sebaceous tumors (approximately 50 percent) as well as relatively high rates of germline variants detected in IHC-positive tumors (approximately 20 to 30 percent) [<a href="#rid40">40-43</a>].</p><p>However, others suggest a targeted use of IHC, based on consideration of the patient's age, clinical presentation, and personal history of Lynch-related tumors [<a href="#rid44">44</a>]. An expert panel suggested the following criteria as appropriate for testing sebaceous tumors with a four-antibody IHC panel  (<a class="graphic graphic_algorithm graphicRef131495" href="/z/d/graphic/131495.html" rel="external">algorithm 1</a>) [<a href="#rid44">44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One sebaceous tumor in a non-head and neck location (only in patients<strong> ≤60 years</strong>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple sebaceous tumors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumors most typically associated with Muir-Torre syndrome (sebaceous adenoma, sebaceous epithelioma, sebaceous carcinoma)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keratoacanthoma with sebaceous differentiation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cystic sebaceous neoplasms, including true sebaceous cysts</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of Lynch syndrome-related, visceral malignancy (eg, colorectal carcinoma, endometrial carcinoma, urothelial carcinoma)</p><p></p><p>Of note, tumor testing is generally <strong>not</strong> recommended for periocular sebaceous tumors, including sebaceous carcinoma, based on evidence that periocular tumors are in most cases sporadic and not associated with increased risk of internal cancers [<a href="#rid45">45,46</a>]. However, the decision to test periocular sebaceous tumors, especially in younger patients, must be considered on a case-by-case basis [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H253202037"><span class="h3">Immunohistochemistry</span><span class="headingEndMark"> — </span>Immunohistochemistry (IHC) testing of sebaceous tumors for MMR proteins (MSH2, MLH1, MSH6, and PMS2) is a relatively simple method that can be performed on formalin-fixed, paraffin-embedded sections as the initial screening test for individuals with suspected Muir-Torre syndrome [<a href="#rid22">22,39</a>]. In a large series of 282 sebaceous neoplasms, loss of MSH2 and MSH6 protein expression was the most frequent pattern observed [<a href="#rid47">47</a>]. (See <a class="local">'Indications for tumor testing'</a> above.)</p><p>The positive predictive value for Muir-Torre syndrome has been estimated to be 55 percent in unselected sebaceous tumors demonstrating loss of both MSH2 and MSH6, 100 percent for tumors with loss of both MLH1 and MSH6, and 100 percent for tumors demonstrating loss of all three MMR proteins [<a href="#rid22">22</a>].</p><p>For patients with lesions showing loss of MMR proteins, MSI analysis of tumor tissue and/or germline mutational analysis is warranted to confirm or rule out the diagnosis of Muir-Torre syndrome. (See <a class="local">'Microsatellite instability analysis'</a> below and <a class="local">'Genetic testing'</a> below.)</p><p>MSI analysis of tumor tissue is also indicated in cases in which MLH1 or MSH2 are expressed on IHC but the clinical suspicion of Muir-Torre syndrome persists. (See <a class="local">'Microsatellite instability analysis'</a> below.)</p><p class="headingAnchor" id="H253202111"><span class="h3">Microsatellite instability analysis</span><span class="headingEndMark"> — </span>Microsatellite instability (MSI) is the hallmark of MMR gene deficiency and is found in approximately two-thirds of sebaceous tumors associated with Muir-Torre syndrome [<a href="#rid24">24,48,49</a>]. MSI analysis can be performed on paraffin-embedded tissue and typically uses five markers (the Bethesda panel including three dinucleotide [D2S123, D5S346, and D17S250] and two mononucleotide [BAT25, BAT26] repeats) [<a href="#rid10">10</a>]. Detection of MSI in any two of the five markers is considered a positive result.</p><p>Because of its greater complexity, cost, and limited availability, MSI analysis should be considered a second-line test in cases in which the IHC results are inconclusive, especially in patients with a family history supporting the suspicion of Muir-Torre syndrome or Lynch syndrome. (See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Microsatellite instability testing'</a>.)</p><p class="headingAnchor" id="H253202173"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Based on expert recommendations, genetic testing for germline variants in the <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em>, and <em>PMS2</em> genes should be offered in the following situations  (<a class="graphic graphic_algorithm graphicRef131495" href="/z/d/graphic/131495.html" rel="external">algorithm 1</a>) [<a href="#rid36">36,40,45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a Mayo Muir-Torre syndrome risk score <strong>≥2</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <strong>extraocular</strong> sebaceous carcinoma and a Mayo Muir-Torre syndrome risk score <strong>≥2</strong>. Genetic testing is generally <strong>not</strong> recommended for periocular sebaceous carcinoma [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Young patients (&lt;50 years) with their first sebaceous carcinoma, with loss of MMR protein expression on IHC and not otherwise meeting the Mayo risk score threshold [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with any sebaceous tumors that screened positive for loss of MMR protein expression on IHC or MSI.</p><p></p><p>Testing for variants in <em>MUTYH </em>should be considered for patients in whom a pathogenic variant in MMR genes is not detected. Germline biallelic inactivation of the base excision repair gene mutY homolog (<em>MUTYH</em>)<em> </em>on chromosome 1p causes a variant of Muir-Torre syndrome, called Muir-Torre syndrome type 2, which is inherited in an autosomal recessive manner [<a href="#rid2">2,14</a>]. (See <a class="local">'MUTYH gene'</a> above and  <a class="medical medical_review" href="/z/d/html/86140.html" rel="external">"<i>MUTYH</i>-associated polyposis"</a>.)</p><p>The absence of a detectable germline variant in MMR genes and <em>MUTYH</em> in patients with tumors showing MMR deficiency warrants further tumor analysis for biallelic somatic MMR mutations or hypermethylation of the promoter region of <em>MLH1</em> [<a href="#rid42">42,50</a>].</p><p class="headingAnchor" id="H253202179"><span class="h1">CANCER SCREENING AND MANAGEMENT</span><span class="headingEndMark"> — </span>Cutaneous neoplasms and synchronous, visceral neoplasms associated with Muir-Torre syndrome should be managed in the individual patient according to available options discussed in separate topic reviews. The management of sebaceous carcinoma is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/97893.html" rel="external">"Sebaceous carcinoma", section on 'Management'</a>.)</p><p>The estimated lifetime risk of colorectal cancer is 40 to 70 percent, stomach cancer 6 to 13 percent, endometrial cancer 15 percent, ovary cancer 4 to 12 percent, and urinary cancers 5 to 21 percent [<a href="#rid51">51,52</a>]. Thus, patients diagnosed with Muir-Torre syndrome and at-risk family members (first-degree relatives) should undergo a preventive cancer screening program similar to that indicated for patients with Lynch syndrome (see  <a class="medical medical_review" href="/z/d/html/15804.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management"</a>), which involves:</p><p class="bulletIndent1"><span class="glyph">●</span>Annual skin examination for lesions suspicious for sebaceous carcinoma or keratoacanthoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy every one to two years, beginning at age 20 to 25 years, or two to five years before the youngest age of diagnosis of colorectal cancer in the family, if diagnosed before age 25 years; annual colonoscopy in carriers of <em>MLH1</em> and <em>MSH2</em> mutations; consider colonoscopy starting at age 30 years in <em>MSH6</em> mutation carriers and 35 years in <em>PMS2</em> mutation carriers, unless an early-onset cancer exists in a given family.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Annual screening for endometrial and ovarian cancer with pelvic examination, endometrial biopsy, and transvaginal ultrasound beginning at age 30 to 35 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upper endoscopy with biopsy of the gastric antrum starting at 30 to 35 years and subsequent surveillance every two to three years can be considered based on patient risk factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Annual urinalysis and cytologic examination beginning at age 30 to 35 years.</p><p></p><p>Nearly one-half of patients with Muir-Torre syndrome have two or more internal malignancies in different locations [<a href="#rid53">53,54</a>]. A baseline and annual positron emission tomography/computerized tomography (PET/CT) scan may be a useful whole-body search for primary malignancies and disease spread [<a href="#rid55">55</a>]. However, its utility compared with the above screening tests has not been determined.</p><p class="headingAnchor" id="H424089536"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/126519.html" rel="external">"Society guideline links: Sebaceous carcinoma and Muir-Torre syndrome"</a>.)</p><p class="headingAnchor" id="H253202764"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Muir-Torre syndrome is a rare, autosomal dominant condition caused by germline inactivating variants in the DNA mismatch repair (MMR) genes <em>MLH1</em>, <em>MSH2</em>,<em> MSH6</em>, and <em>PMS2</em>. In approximately one-third of patients, Muir-Torre syndrome type 2 is associated with germline biallelic inactivation of the base excision repair gene <em>MUTYH</em> and inherited in an autosomal recessive manner. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'MUTYH gene'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Muir-Torre syndrome is characterized by the association of at least one sebaceous skin tumor and at least one visceral malignancy and is considered a phenotypic variant of hereditary nonpolyposis colorectal carcinoma syndrome (HNPCC; Lynch syndrome). Sebaceous adenomas  (<a class="graphic graphic_picture graphicRef98399" href="/z/d/graphic/98399.html" rel="external">picture 2A</a>), sebaceous epitheliomas, sebaceous carcinomas  (<a class="graphic graphic_picture graphicRef70403" href="/z/d/graphic/70403.html" rel="external">picture 2B</a>), and keratoacanthomas  (<a class="graphic graphic_picture graphicRef73408" href="/z/d/graphic/73408.html" rel="external">picture 1</a>) are the most typical cutaneous tumors associated with Muir-Torre syndrome. Visceral neoplasms include colorectal, endometrial, ovarian, and urothelial cancers. (See <a class="local">'Clinical manifestations'</a> above and  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of Muir-Torre syndrome is based upon the combination of clinical criteria, tumor testing for deficiency of MMR protein or microsatellite instability (MSI), and genetic testing for germline variants in MMR genes  (<a class="graphic graphic_algorithm graphicRef131495" href="/z/d/graphic/131495.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnostic approach'</a> above and <a class="local">'Clinical criteria (the Mayo Muir-Torre syndrome risk score)'</a> above and <a class="local">'Tumor testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer screening and management </strong>– Patients diagnosed with Muir-Torre syndrome and at-risk family members (first-degree relatives) should undergo a preventive cancer screening program for colorectal cancers starting at age 20 to 25 years (or earlier if colorectal cancer was diagnosed in the family before age 25 years) and stomach and urogenital cancers starting at the age of 30 to 35 years. (See <a class="local">'Cancer screening and management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005; 6:980.</a></li><li><a class="nounderline abstract_t">John AM, Schwartz RA. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management. J Am Acad Dermatol 2016; 74:558.</a></li><li><a class="nounderline abstract_t">Le S, Ansari U, Mumtaz A, et al. Lynch Syndrome and Muir-Torre Syndrome: An update and review on the genetics, epidemiology, and management of two related disorders. Dermatol Online J 2017; 23.</a></li><li><a class="nounderline abstract_t">Shah KR, Boland CR, Patel M, et al. Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol 2013; 68:189.e1.</a></li><li><a class="nounderline abstract_t">Win AK, Jenkins MA, Dowty JG, et al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2017; 26:404.</a></li><li><a class="nounderline abstract_t">Ponti G, Pellacani G, Seidenari S, et al. Cancer-associated genodermatoses: skin neoplasms as clues to hereditary tumor syndromes. Crit Rev Oncol Hematol 2013; 85:239.</a></li><li><a class="nounderline abstract_t">Shaw KC, Altmayer SA, Driscoll MS. Muir-Torre syndrome: multiple sebaceous neoplasms and visceral malignancy manifesting after cardiac transplantation and iatrogenic immunosuppression. Int J Dermatol 2017; 56:e26.</a></li><li><a class="nounderline abstract_t">Tomonari M, Shimada M, Nakada Y, et al. Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report. BMC Nephrol 2019; 20:394.</a></li><li><a class="nounderline abstract_t">Duarte M, Milikowski C. Gastrointestinal polyposis with associated cutaneous manifestations. Pathology 2022; 54:157.</a></li><li><a class="nounderline abstract_t">Mahalingam M. MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots. Am J Dermatopathol 2017; 39:239.</a></li><li><a class="nounderline abstract_t">Machin P, Catasus L, Pons C, et al. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. J Cutan Pathol 2002; 29:415.</a></li><li><a class="nounderline abstract_t">Kruse R, Rütten A, Lamberti C, et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 1998; 63:63.</a></li><li><a class="nounderline abstract_t">Perera S, Ramyar L, Mitri A, et al. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome. J Hum Genet 2010; 55:37.</a></li><li><a class="nounderline abstract_t">Ponti G, Ponz de Leon M, Maffei S, et al. Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. Clin Genet 2005; 68:442.</a></li><li><a class="nounderline abstract_t">Russell AM, Zhang J, Luz J, et al. Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients. Int J Cancer 2006; 118:1937.</a></li><li><a class="nounderline abstract_t">Cino D, Drumm C, Sheahan K, et al. Muir-Torre syndrome: a case of unusual coexisting genetic mutations. Clin Exp Dermatol 2022; 47:602.</a></li><li><a class="nounderline abstract_t">Ajith Kumar VK, Gold JA, Mallon E, et al. Sebaceous adenomas in an MYH associated polyposis patient of Indian (Gujarati) origin. Fam Cancer 2008; 7:187.</a></li><li><a class="nounderline abstract_t">Guillén-Ponce C, Castillejo A, Barberá VM, et al. Biallelic MYH germline mutations as cause of Muir-Torre syndrome. Fam Cancer 2010; 9:151.</a></li><li><a class="nounderline abstract_t">Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol 2011; 65:1054.</a></li><li><a class="nounderline abstract_t">Ponti G, Pellacani G, Ruini C, et al. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients. Fam Cancer 2014; 13:553.</a></li><li><a class="nounderline abstract_t">Ponti G, Manfredini M, Pellacani G, Tomasi A. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome. Clin Chem Lab Med 2016; 54:1725.</a></li><li><a class="nounderline abstract_t">Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol 2009; 36:613.</a></li><li><a class="nounderline abstract_t">Singh RS, Grayson W, Redston M, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol 2008; 32:936.</a></li><li><a class="nounderline abstract_t">Ponti G, Losi L, Di Gregorio C, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 2005; 103:1018.</a></li><li><a class="nounderline abstract_t">Bhaijee F, Brown AS. Muir-Torre syndrome. Arch Pathol Lab Med 2014; 138:1685.</a></li><li><a class="nounderline abstract_t">Kennedy RA, Thavaraj S, Diaz-Cano S. An Overview of Autosomal Dominant Tumour Syndromes with Prominent Features in the Oral and Maxillofacial Region. Head Neck Pathol 2017; 11:364.</a></li><li><a class="nounderline abstract_t">Ponti G, Meschieri A, Pollio A, et al. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy. J Oral Pathol Med 2015; 44:552.</a></li><li><a class="nounderline abstract_t">Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 1995; 33:90.</a></li><li><a class="nounderline abstract_t">Cohen PR, Kohn SR, Davis DA, Kurzrock R. Muir-Torre syndrome. Dermatol Clin 1995; 13:79.</a></li><li><a class="nounderline abstract_t">Tailor IK, Cook J, Reilly JT, et al. Acute myeloid leukaemia associated with Muir-Torre variant of hereditary non-polyposis colon cancer (HNPCC): implications for inherited and acquired mutations in DNA mismatch repair genes. Br J Haematol 2012; 156:289.</a></li><li><a class="nounderline abstract_t">Kamisasanuki T, Uchino E, Fukushima J, et al. A case of Muir-Torre syndrome with multiple cancers of bilateral eyelids and breast. Korean J Ophthalmol 2013; 27:204.</a></li><li><a class="nounderline abstract_t">Tanyi M, Olasz J, Lukács G, et al. A new mutation in Muir-Torre syndrome associated with familiar transmission of different gastrointestinal adenocarcinomas. Eur J Surg Oncol 2009; 35:1128.</a></li><li><a class="nounderline abstract_t">Nolan L, Eccles D, Cross E, et al. First case report of Muir-Torre syndrome associated with non-small cell lung cancer. Fam Cancer 2009; 8:359.</a></li><li><a class="nounderline abstract_t">Vernez M, Hutter P, Monnerat C, et al. A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Cancer 2007; 6:141.</a></li><li><a class="nounderline abstract_t">Cohen PR. Muir-Torre syndrome in patients with hematologic malignancies. Am J Hematol 1992; 40:64.</a></li><li><a class="nounderline abstract_t">Roberts ME, Riegert-Johnson DL, Thomas BC, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med 2014; 16:711.</a></li><li><a class="nounderline abstract_t">Kibbi N, Worley B, Owen JL, et al. Sebaceous carcinoma: controversies and their evidence for clinical practice. Arch Dermatol Res 2020; 312:25.</a></li><li><a class="nounderline abstract_t">Eiger-Moscovich M, Eagle RC Jr, Shields CL, et al. Muir-Torre Syndrome Associated Periocular Sebaceous Neoplasms: Screening Patterns in the Literature and in Clinical Practice. Ocul Oncol Pathol 2020; 6:226.</a></li><li><a class="nounderline abstract_t">Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol 2008; 21:159.</a></li><li><a class="nounderline abstract_t">Everett JN, Raymond VM, Dandapani M, et al. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol 2014; 150:1315.</a></li><li><a class="nounderline abstract_t">Boennelycke M, Thomsen BM, Holck S. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases. Pathol Res Pract 2015; 211:78.</a></li><li><a class="nounderline abstract_t">Kunnackal John G, Das Villgran V, Caufield-Noll C, Giardiello FM. Comparison of universal screening in major lynch-associated tumors: a systematic review of literature. Fam Cancer 2022; 21:57.</a></li><li><a class="nounderline abstract_t">Cook S, Pethick J, Kibbi N, et al. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018. J Am Acad Dermatol 2023; 89:1129.</a></li><li><a class="nounderline abstract_t">Task Force/Committee Members, Vidal CI, Sutton A, et al. Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores. J Cutan Pathol 2019; 46:484.</a></li><li><a class="nounderline abstract_t">Owen JL, Kibbi N, Worley B, et al. Sebaceous carcinoma: evidence-based clinical practice guidelines. Lancet Oncol 2019; 20:e699.</a></li><li><a class="nounderline abstract_t">Rajan Kd A, Burris C, Iliff N, et al. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma. Am J Ophthalmol 2014; 157:640.</a></li><li><a class="nounderline abstract_t">Walsh MD, Jayasekara H, Huang A, et al. Clinico-pathological predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a single Australian private pathology service. Australas J Dermatol 2019; 60:126.</a></li><li><a class="nounderline abstract_t">Entius MM, Keller JJ, Drillenburg P, et al. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 2000; 6:1784.</a></li><li><a class="nounderline abstract_t">Fernandez-Flores A. Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to Muir-Torre syndrome. Am J Dermatopathol 2012; 34:416.</a></li><li><a class="nounderline abstract_t">Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Kim JC, Bodmer WF. Genotypic and Phenotypic Characteristics of Hereditary Colorectal Cancer. Ann Coloproctol 2021; 37:368.</a></li><li><a class="nounderline abstract_t">Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110:223.</a></li><li><a class="nounderline abstract_t">Coldron J, Reid I. Muir-Torre syndrome. J R Coll Surg Edinb 2001; 46:178.</a></li><li><a class="nounderline abstract_t">Akhtar S, Oza KK, Khan SA, Wright J. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 1999; 41:681.</a></li><li><a class="nounderline abstract_t">Ishiguro Y, Homma S, Yoshida T, et al. Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two cases. Surg Case Rep 2017; 3:71.</a></li></ol></div><div id="topicVersionRevision">Topic 98605 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16321766" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26892655" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Muir-Torre syndrome (MTS): An update and approach to diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29447627" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lynch Syndrome and Muir-Torre Syndrome: An update and review on the genetics, epidemiology, and management of two related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23317980" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cutaneous manifestations of gastrointestinal disease: part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27799157" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22823951" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cancer-associated genodermatoses: skin neoplasms as clues to hereditary tumor syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27868185" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Muir-Torre syndrome: multiple sebaceous neoplasms and visceral malignancy manifesting after cardiac transplantation and iatrogenic immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31664942" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34763900" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gastrointestinal polyposis with associated cutaneous manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323777" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12139636" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9634524" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911012" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16207212" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16287072" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34762321" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Muir-Torre syndrome: a case of unusual coexisting genetic mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17874208" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sebaceous adenomas in an MYH associated polyposis patient of Indian (Gujarati) origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19998059" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Biallelic MYH germline mutations as cause of Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21550136" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24969397" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27016151" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19515040" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18551751" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15662714" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427047" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110467" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : An Overview of Autosomal Dominant Tumour Syndromes with Prominent Features in the Oral and Maxillofacial Region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25213213" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7601953" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Muir-Torre syndrome: a 25-year retrospect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7712655" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21910719" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute myeloid leukaemia associated with Muir-Torre variant of hereditary non-polyposis colon cancer (HNPCC): implications for inherited and acquired mutations in DNA mismatch repair genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23730114" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A case of Muir-Torre syndrome with multiple cancers of bilateral eyelids and breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19423266" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A new mutation in Muir-Torre syndrome associated with familiar transmission of different gastrointestinal adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19449129" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : First case report of Muir-Torre syndrome associated with non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17051350" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1566750" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Muir-Torre syndrome in patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603434" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471636" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sebaceous carcinoma: controversies and their evidence for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33005611" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Muir-Torre Syndrome Associated Periocular Sebaceous Neoplasms: Screening Patterns in the Literature and in Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18065960" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006859" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25457183" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33426601" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of universal screening in major lynch-associated tumors: a systematic review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37031776" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30895633" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31797796" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sebaceous carcinoma: evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321472" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30506759" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinico-pathological predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a single Australian private pathology service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815898" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123265" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33530449" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34961301" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Genotypic and Phenotypic Characteristics of Hereditary Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645574" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11478018" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534628" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28537014" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
